Product Description
BLX-028914, a selective phosphodiesterase-4 (PDE4) inhibitor with a promising safety profile,is currently under development for treatment of airway diseases by Orexo AB, Sweden. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00758446)
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dart NeuroScience
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Rhinitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2008-001179-30 | P2 |
Completed |
Rhinitis, Allergic |
2008-12-18 |
2022-03-12 |
Treatments |
|
| OX914-001 | P2 |
Completed |
Rhinitis, Allergic |
2008-12-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|